Overview

Update
Total Equity Funding
$139.5M in 7 Rounds from 7 Investors
Most Recent Funding
$33M Series E on October 29, 2014
Headquarters:
Hardwick, MA
Description:
Aileron Therapeutics is a biopharmaceutical company that develops a class of drugs called Stapled Peptides.
Founders:
Categories:
Biopharma, Therapeutics, Biotechnology
Website:
http://www.aileronrx.com

Company Details

Update

Aileron Therapeutics (formerly Renegade Therapeutics) is a biopharmaceutical company that was founded in 2005 to develop and advance a class of drugs called Stapled Peptides. Stapled Peptides represent the first general solution, or "scaffold" for modulating intracellular protein-protein interactions that are critical control points to nearly all functions of a cell. The ability to target and regulate these control points affords the unique opportunity to exploit potentially thousands of currently "undruggable" cellular targets with applications in all human diseases.

Aileron’s proprietary technology locks peptides into their biologically active shape, mimicking the structures found in nature, and ultimately endows the peptide with unique properties, including efficient cell penetration, high affinity binding to large target protein surfaces and excellent stability within the body.

Funding Rounds (7) - $139.5M

Update
DateAmount / RoundValuationLead InvestorInvestors
Oct, 2014$33M / Series E7
Nov, 2013$30M / Series E6
Jan, 2013$12M / Series D6
Jun, 2009$40M / Series D6
Apr, 2008$10.5M / Series C2
Jun, 2007$7M / Series B2
Dec, 2006$7M / Series A2

Current Team (4)

Update

Offices/Locations (2)

Update
  • Office

    Cambridge, MA

    USA

  • HQ

    840 Memorial Drive, 2nd Floor

    Cambridge

    Hardwick, MA MA 02139

    USA

Past Team (2)

Update

Images (1)

Update

Add Acquisitions

Add Products

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Videos